The SPTB antibody targets spectrin beta chain, a key component of the erythrocyte membrane skeleton. Spectrin, composed of alpha (SPTA1) and beta (SPTB) subunits, forms a flexible network with actin and other proteins, maintaining red blood cell (RBC) shape, stability, and deformability. Mutations in the SPTB gene are linked to hereditary hemolytic anemias, notably hereditary spherocytosis (HS) and elliptocytosis, characterized by fragile, misshapen RBCs prone to hemolysis.
SPTB antibodies are widely used in research to study RBC membrane integrity, cytoskeletal organization, and disease mechanisms. In diagnostics, they help detect spectrin deficiencies or abnormalities in suspected HS cases through techniques like immunofluorescence, Western blotting, or flow cytometry. Additionally, these antibodies aid in exploring non-erythroid roles of SPTB, such as neuronal development and cardiac function, where spectrin contributes to cell signaling and structural support.
As a critical tool in hematology and cell biology, SPTB antibodies advance understanding of cytoskeletal disorders and potential therapeutic targets. Their specificity enables precise analysis of spectrin expression, post-translational modifications, and interactions, supporting both basic science and clinical applications.